Federal Register Notice
Amgen Inc. and Horizon Therapeutics plc; Analysis of Agreement Containing Consent Order To Aid Public Comment
Date
Displaying 61 - 80 of 346
FTC Reaches Proposed Settlement with Surescripts in Illegal Monopolization Case
Date
The Federal Trade Commission filed a proposed order that would prohibit health information technology company Surescripts from engaging in exclusionary conduct and executing or enforcing non-compete...
Statement of Chair Lina M. Khan Regarding the Policy Statement Concerning Reliance on Prior PBM-Related Advocacy Statements and Reports
Date
By
Lina M. Khan, Former Chair and Commissioner
FTC Votes to Issue Statement Withdrawing Prior Pharmacy Benefit Manager Advocacy
Date
The Federal Trade Commission voted to issue a statement cautioning against reliance on prior advocacy statements and studies related to pharmacy benefit mangers (PBMs) that no longer reflect current...
FTC Announces Tentative Agenda for July 20 Open Commission Meeting
Date
Today, Federal Trade Commission Chair Lina M. Khan announced that an open meeting of the Commission will be held virtually on Thursday, July 20, 2023. The open meeting will commence at 11am ET and...
FTC Files Amicus Brief in Bystolic Antitrust Litigation Supporting Competition in the Hypertension Drug Market
Date
The Federal Trade Commission filed a friend-of-the-court (amicus) brief in the U.S. Court of Appeals for the Second Circuit, clarifying the legal standards that apply in certain antitrust cases...
FTC Further Expands Inquiry Into Prescription Drug Middlemen Industry Practices
Date
As part of its ongoing study on pharmacy benefit managers (PBMs) and their impact on the accessibility and affordability of prescription drugs, the Federal Trade Commission has issued a compulsory...
FTC, DOJ Issue Summary on Joint Pharmaceutical Merger Analysis Workshop
Date
The Federal Trade Commission and the U.S. Department of Justice, Antitrust Division released a summary of a two-day workshop that explored new approaches to enforcement of the antitrust laws in the...
FTC Deepens Inquiry into Prescription Drug Middlemen
Date
As part of its ongoing inquiry into pharmacy benefit managers (PBMs) and their impact on the accessibility and affordability of prescription drugs, the Federal Trade Commission has issued compulsory...
Amgen Inc. and Horizon Therapeutics plc, FTC v.
Type of Action
Federal
Last Updated
FTC Matter/File Number
231 0037
Case Status
Pending
Sage Chemical, Inc. et al. v. Supernus Pharmaceuticals, Inc. et al.
Date
Federal Court
District of Delaware
The Federal Trade Commission filed an amicus brief with the U.S. District Court for the District of Delaware in the case of Sage Chemical, Inc. et al. v. Supernus Pharmaceuticals, Inc. et al. The...
File
Endo Pharmaceuticals Inc./Amneal Pharmaceuticals, Inc.
The FTC is suing Endo Pharmaceuticals, Inc., Endo International plc, Impax Laboratories, LLC, and Impax’s owner, Amneal Pharmaceuticals, Inc., alleging that a 2017 agreement between Endo and Impax violated the antitrust laws by eliminating competition in the market for oxymorphone ER. The complaint charges the defendants with violating Sections 1 and 2 of the Sherman Act, which constitutes unfair methods of competition in violation of Section 5 of the FTC Act. Specifically, Endo, Impax, and Amneal are charged with entering into an illegal agreement in restraint of trade, and Amneal is charged with monopolization of the oxymorphone ER market. The complaint was filed in the U.S. District Court for the District of Columbia on Jan. 25, 2021.
Type of Action
Federal
Last Updated
FTC Matter/File Number
1910104
FTC Asks Federal Court to Hold ‘Pharma Bro’ Martin Shkreli in Contempt
Date
The Federal Trade Commission asked a federal judge to hold “Pharma Bro” Martin Shkreli in contempt for failing to provide the FTC with information needed to determine whether he is violating a...
Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC
Date
Citation Number
1:21-cv-00691
Federal Court
District of Delaware
The Federal Trade Commission filed an amicus brief with the U.S. District Court for the District of Delaware in the case of Jazz Pharmaceuticals v. Avadel CNS Pharmaceuticals. The Brief highlights the...
File
Statement of Commissioner Rebecca Kelly Slaughter Regarding the Policy Statement of the Federal Trade Commission on Rebates and Fees in Exchange for Excluding Lower-Cost Drug Products
Date
By
Rebecca Kelly Slaughter, Former Commissioner
Matter Number
P221201
Displaying 61 - 80 of 346